ロード中...
First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease
BACKGROUND: In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer’s disease (AD) after infusion of a humanized monoclonal antibody to amyloid β, AAB-003 (NCT01193608; re...
保存先:
| 出版年: | Alzheimers Res Ther |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4772335/ https://ncbi.nlm.nih.gov/pubmed/26925577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-016-0177-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|